BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

BioAge Labs, Inc.NASDAQ: BIOA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $7.67M rose 13.1% year over year, behind the +27.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 9.6% from the prior quarter. Over 3 fiscal years it compounded at +43.3% a year.

Context

  • Selling, general & admin amounted to 309.2% of revenue in FY2025.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 9 analysts of $9.93M (-64.3%) for the fiscal year ending Dec 2026, a slowdown from the +45.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.67M+9.6% QoQ
Last fiscal yearDec 2025
$27.81M+45.2% YoY
LTMMar 2026
$28.7M+27.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.1%-68.9%-82.0 pp
1 year+45.2%-64.3%-109.5 pp
3-year CAGR+43.3%-50.0%-93.3 pp
5-year CAGR+17.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
27.81M USD
Year-over-year change
+45.2%
3-year CAGR
+43.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.8% is the highest of 9, against a peer median of -7.7%.
  • Selling, general & admin amounts to 278.2% of revenue for BIOA, versus a peer median of 59.3%.
BIOA Competitors
Selling, General & Admin for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$166.84M CAD+0.2%+0.7%53.7%
CGCCanopy Growth CorporationLTM Mar 2026CA$134.01M CAD+10.1%-9.2%42.9%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M USD-11.2%-10.5%—
EDITEditas Medicine, Inc.LTM Mar 2026$46.76M USD-29.2%-11.0%120.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$33.33M USD—+8.3%24.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M USD-34.0%-12.3%—
BIOABioAge Labs, Inc.LTM Mar 2026$28.7M USD+27.8%+43.3%278.2%
CABACabaletta Bio, Inc.LTM Mar 2026$28.39M USD-5.3%+25.8%—
HUMAHumacyte, Inc.LTM Mar 2026$27.31M USD-10.2%+10.9%1354.8%
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.13M USD-1.6%-10.3%64.9%
Peer median (excluding BIOA) —-7.7%-9.2%59.3%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.